Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study [0.03%]
法国真实世界中纳武单抗在晚期非小细胞肺癌中的使用和免疫治疗再挑战的结果：LIST研究的中期结果
Benoît Godbert,Elisa Gobbini,Chantal Decroisette et al.
Benoît Godbert et al.
Introduction: Nivolumab is approved in France as monotherapy for the treatment of advanced (locally advanced or metastatic) non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence The...
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [0.03%]
zanubrutinib与初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者奥妥珠单抗联合维纳妥拉的疗效和安全性非劣性间接比较研究
Talha Munir,Nicolás Martinez-Calle,Sheng Xu et al.
Talha Munir et al.
Introduction: Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted...
Part 3 (Podcast): From Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence [0.03%]
第三部分（播客）：从怀疑者到支持者——一场关于肿瘤真实世界证据 sceptic to proponent of Oncology Real World Evidence 的播客对话
Adam Brufsky,Raymond Liu,Joanne C Ryan
Adam Brufsky
The proliferation of modern real-world studies is a relatively recent development in oncology and has been met with skepticism by some clinicians. In this podcast, the hosts share their personal experiences with real-world evidence (RWE) an...
A Practical Approach to Understanding Real-World Study Methodology in Cancer Research: A Vodcast [0.03%]
癌症研究中理解现实世界研究方法论的实用途径——vodcast视频讲座
Adam Brufsky,Winson Cheung,Joanne C Ryan
Adam Brufsky
Real-world studies have become more common in clinical literature in recent years, but many clinicians remain unfamiliar with real-world study design and statistical approaches. This vodcast intends to be a practical guide for clinicians by...
Real-World Studies and Randomized Controlled Trials: A Podcast Discussion of the Relative Strengths and Limitations of These Complementary Designs for Cancer Research [0.03%]
真实世界研究和随机对照试验：癌症研究中这些互补设计的相对优缺点播客讨论
Adam Brufsky,Christos Vaklavas,Joanne C Ryan
Adam Brufsky
Randomized controlled trials (RCTs) are the benchmark for assessing the safety and efficacy of treatments but are subject to some inherent limitations, such as restrictive inclusion criteria and underrepresentation of certain patient groups...
Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection [0.03%]
帕博利珠单抗诱导的高炎症泛髓病：神经化学标志物对中枢神经系统受累严重程度的影响
Beate Hagenkötter,Jérôme De Sèze,Faten Hammami et al.
Beate Hagenkötter et al.
This is the first documented case of recurrent, severe, and highly inflammatory panmyelitis induced by pembrolizumab. A 41-year-old woman with nodular melanoma developed tetraparesis after three cycles of pembrolizumab treatment. Spinal mag...
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer [0.03%]
德利菲301研究二期试验中既往治疗过的小细胞肺癌的亚洲亚组分析
Myung-Ju Ahn,Byoung Chul Cho,Kadoaki Ohashi et al.
Myung-Ju Ahn et al.
Introduction: Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer c...
Correction: Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer [0.03%]
高风险子宫内膜癌复发性疾病临床负担的更正通知
Kalé Kponee-Shovein,Vimalanand S Prabhu,Yan Song et al.
Kalé Kponee-Shovein et al.
Published Erratum
Oncology and therapy. 2025 Sep 4. DOI:10.1007/s40487-025-00373-z 2025
The Impact of the COVID-19 Pandemic on an Immunocompromised Patient with Allogeneic Haematopoietic Stem Cell Transplant: A Dual Perspective from Patient and Physician Standpoints [0.03%]
Covid-19大流行对allo-HSCT后免疫重建患者的影響——来自患者和医师的双重观点
Stephanie Nguyen,Isabelle
Stephanie Nguyen
This collaborative article is co-authored by a haematologist and her patient who was immunocompromised following a bone marrow transplant for acute myeloid leukaemia (AML), which was probably chemotherapy-induced following treatment for a B...
A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor [0.03%]
pexidartinib治疗东亚地区滑膜肉瘤疗效和安全性的3期研究
Hairong Xu,Po-Kuei Wu,Zhaoming Ye et al.
Hairong Xu et al.
Introduction: The aim of this study was to assess the efficacy and safety of pexidartinib, an inhibitor of colony-stimulating factor 1 receptor, in East Asian patients with tenosynovial giant cell tumor (TGCT). ...